All You Need to Know About UCB (UCBJY) Rating Upgrade to Strong Buy

22.08.25 18:00 Uhr

Werte in diesem Artikel
Aktien

209,70 EUR -0,20 EUR -0,10%

Indizes

4.807,6 PKT 1,2 PKT 0,02%

PKT PKT

571,0 PKT 1,0 PKT 0,17%

1.604,2 PKT 3,6 PKT 0,22%

UCB SA (UCBJY) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #1 (Strong Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.The Zacks rating relies solely on a company's changing earnings picture. It tracks EPS estimates for the current and following years from the sell-side analysts covering the stock through a consensus measure -- the Zacks Consensus Estimate.The power of a changing earnings picture in determining near-term stock price movements makes the Zacks rating system highly useful for individual investors, since it can be difficult to make decisions based on rating upgrades by Wall Street analysts. These are mostly driven by subjective factors that are hard to see and measure in real time.Therefore, the Zacks rating upgrade for UCB basically reflects positivity about its earnings outlook that could translate into buying pressure and an increase in its stock price.Most Powerful Force Impacting Stock PricesThe change in a company's future earnings potential, as reflected in earnings estimate revisions, has proven to be strongly correlated with the near-term price movement of its stock. The influence of institutional investors has a partial contribution to this relationship, as these big professionals use earnings and earnings estimates to calculate the fair value of a company's shares. An increase or decrease in earnings estimates in their valuation models simply results in higher or lower fair value for a stock, and institutional investors typically buy or sell it. Their transaction of large amounts of shares then leads to price movement for the stock.For UCB, rising earnings estimates and the consequent rating upgrade fundamentally mean an improvement in the company's underlying business. And investors' appreciation of this improving business trend should push the stock higher.Harnessing the Power of Earnings Estimate RevisionsAs empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock movements, tracking such revisions for making an investment decision could be truly rewarding. Here is where the tried-and-tested Zacks Rank stock-rating system plays an important role, as it effectively harnesses the power of earnings estimate revisions.The Zacks Rank stock-rating system, which uses four factors related to earnings estimates to classify stocks into five groups, ranging from Zacks Rank #1 (Strong Buy) to Zacks Rank #5 (Strong Sell), has an impressive externally-audited track record, with Zacks Rank #1 stocks generating an average annual return of +25% since 1988. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here >>>> .Earnings Estimate Revisions for UCBThis company is expected to earn $4.32 per share for the fiscal year ending December 2025, which represents no year-over-year change.Analysts have been steadily raising their estimates for UCB. Over the past three months, the Zacks Consensus Estimate for the company has increased 2.8%.Bottom LineUnlike the overly optimistic Wall Street analysts whose rating systems tend to be weighted toward favorable recommendations, the Zacks rating system maintains an equal proportion of "buy" and "sell" ratings for its entire universe of more than 4,000 stocks at any point in time. Irrespective of market conditions, only the top 5% of the Zacks-covered stocks get a "Strong Buy" rating and the next 15% get a "Buy" rating. So, the placement of a stock in the top 20% of the Zacks-covered stocks indicates its superior earnings estimate revision feature, making it a solid candidate for producing market-beating returns in the near term.You can learn more about the Zacks Rank here >>> The upgrade of UCB to a Zacks Rank #1 positions it in the top 5% of the Zacks-covered stocks in terms of estimate revisions, implying that the stock might move higher in the near term.One Big Gain, Every Trading DayTo help you take full advantage of this market, you’re invited to access every stock recommendation in all our private portfolios - for just $1.Zacks private portfolio services that closed 256 double and triple-digit winners in 2024 alone. That’s about one big gain every day the market was open. Of course, not all our picks are winners, but members have seen recent gains as high as +627% +1,340%, and +1,708%.Imagine how much you could profit with a steady stream of real-time picks from all our services that cover a number of strategies to suit a variety of investing and trading styles.See Stocks Now >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report UCB SA (UCBJY): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks

Ausgewählte Hebelprodukte auf UCB

Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf UCB

NameHebelKOEmittent
NameHebelKOEmittent
Wer­bung

Quelle: Zacks

Nachrichten zu UCB S.A.

Wer­bung

Analysen zu UCB S.A.

DatumRatingAnalyst
14.12.2012UCB holdDeutsche Bank AG
07.11.2012UCB holdING
30.10.2012UCB outperformExane-BNP Paribas SA
27.09.2012UCB overweightMorgan Stanley
27.09.2012UCB holdING
DatumRatingAnalyst
30.10.2012UCB outperformExane-BNP Paribas SA
27.09.2012UCB overweightMorgan Stanley
17.09.2012UCB overweightMorgan Stanley
02.08.2012UCB buySociété Générale Group S.A. (SG)
23.07.2012UCB overweightMorgan Stanley
DatumRatingAnalyst
14.12.2012UCB holdDeutsche Bank AG
07.11.2012UCB holdING
27.09.2012UCB holdING
03.08.2012UCB holdING
01.12.2011UCB holdSociété Générale Group S.A. (SG)
DatumRatingAnalyst
10.09.2012UCB underperformCheuvreux SA
03.09.2007SCHWARZ PHARMA reduzierenAC Research
07.03.2007SCHWARZ PHARMA Einstellung der CoverageNord LB
27.02.2007SCHWARZ PHARMA verkaufenM.M. Warburg
26.02.2007SCHWARZ PHARMA reduzierenAC Research

Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für UCB S.A. nach folgenden Kriterien zu filtern.

Alle: Alle Empfehlungen

Buy: Kaufempfehlungen wie z.B. "kaufen" oder "buy"
Hold: Halten-Empfehlungen wie z.B. "halten" oder "neutral"
Sell: Verkaufsempfehlungn wie z.B. "verkaufen" oder "reduce"
mehr Analysen